Trial · NCT01767636
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
NCT01767636, Phase 2, Completed, Mayo Clinic; results first posted 2020-04-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer. Trials, record NCT01767636. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01767636
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
- NCT number
- NCT01767636
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 38 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma, Kidney Oncocytoma, Metastatic Renal Cell Cancer, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Interventions
- Pazopanib Hydrochloride
- First posted
- 2013-01-14
- Last updated
- 2025-03-03
- Results first posted
- 2020-04-08
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival Rate at 12 Months | 12 months | Overall survival rate at 12 months is defined as the percentage of participants who are alive at 12 months. |
| Secondary | Number of Participants Experiencing at Least One Toxicity | Up to 2 years | Number of participants experiencing at least one toxicity defined as a grade 3 or higher adverse event deemed at least possible related to treatment. |
| Secondary | Progression-free Survival | From registration to the earliest date documentation of disease progression or death, assessed up to 2 years | Kaplan-Meier curve will be used to estimate progression-free survival time. Progression is defined as At least one of the following must be true:a. At least one new malignant lesion, which also includes any lymph node that was normal at baseline (\< 1.0 cm short axis) and increased to ≥ 1.0 cm short axis during follow-up. b. At least a 20% increase in PBSD (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the MSD. In addition, the PBSD must also demonstrate an absolute increase of at least 0.5 cm from the MSD. |
| Secondary | Overall Survival | Up to 2 years | Overall survival is defined as the time from study registration to death date. |
| Secondary | Number of Participants With Best Response in the First 2 Cycles | Up to 56 days | The number of participants with Best tumor response in the first 2 cycles. Partial Response (PR): At least a 30% decrease in PBSD (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the BSD. Progression is defined as At least one of the following must be true:a. At least one new malignant lesion, which also includes any lymph node that was normal at baseline (\< 1.0 cm short axis) and increased to ≥ 1.0 cm short axis during follow-up. b. At least a 20% increase in PBSD (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the MSD. In addition, the PBSD must also demonstrate an absolute increase of at least 0.5 cm from the MSD.Stable Disease (SD): Neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD taking as reference the MSD. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival Rate at 12 Months | 12 months | Evaluable participants are included in this analysis. | percentage of participants | NUMBER |
| SECONDARY | Number of Participants Experiencing at Least One Toxicity | Up to 2 years | Evaluable participants are included in this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Progression-free Survival | From registration to the earliest date documentation of disease progression or death, assessed up to 2 years | Evaluable participants are included in this analysis. | months | MEDIAN |
| SECONDARY | Overall Survival | Up to 2 years | Evaluable participants are included in this analysis. | months | MEDIAN |
| SECONDARY | Number of Participants With Best Response in the First 2 Cycles | Up to 56 days | Evaluable participants are included in this analysis. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival Rate at 12 Months | Treatment (Pazopanib Hydrochloride) | 65.7 | 90% Confidence Interval 50.5 to 78.9 | percentage of participants | |
| Number of Participants Experiencing at Least One Toxicity | Treatment (Pazopanib Hydrochloride) | 17 | Participants | ||
| Progression-free Survival | Treatment (Pazopanib Hydrochloride) | 7.5 | 90% Confidence Interval 5.0 to 11.0 | months | |
| Overall Survival | Treatment (Pazopanib Hydrochloride) | 18.9 | 90% Confidence Interval 13.0 to NA | months | |
| Number of Participants With Best Response in the First 2 Cycles | Treatment (Pazopanib Hydrochloride) | Partial Response (PR) | 4 | Participants | |
| Number of Participants With Best Response in the First 2 Cycles | Treatment (Pazopanib Hydrochloride) | Stable Disease (SD) | 21 | Participants | |
| Number of Participants With Best Response in the First 2 Cycles | Treatment (Pazopanib Hydrochloride) | Progression (PD) | 3 | Participants | |
| Number of Participants With Best Response in the First 2 Cycles | Treatment (Pazopanib Hydrochloride) | Not Evaluated | 7 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Pazopanib Hydrochloride) | 38 | |
| Overall Study | COMPLETED | Treatment (Pazopanib Hydrochloride) | 35 | |
| Overall Study | NOT COMPLETED | Treatment (Pazopanib Hydrochloride) | 3 |
Source ClinicalTrials.gov
Adverse events76
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Pazopanib Hydrochloride) | 3 | 35 | 5 |
| other | Hypothyroidism | Endocrine disorders | Treatment (Pazopanib Hydrochloride) | 4 | 35 | 7 |
| other | Blurred vision | Eye disorders | Treatment (Pazopanib Hydrochloride) | 1 | 35 | 1 |
| other | Dry eye | Eye disorders | Treatment (Pazopanib Hydrochloride) | 1 | 35 | 1 |
| other | Watering eyes | Eye disorders | Treatment (Pazopanib Hydrochloride) | 1 | 35 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Pazopanib Hydrochloride) | 6 | 35 | 7 |
| other | Constipation | Gastrointestinal disorders | Treatment (Pazopanib Hydrochloride) | 1 | 35 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Pazopanib Hydrochloride) | 23 | 35 | 95 |
| other | Esophageal pain | Gastrointestinal disorders | Treatment (Pazopanib Hydrochloride) | 1 | 35 | 3 |
| other | Flatulence | Gastrointestinal disorders | Treatment (Pazopanib Hydrochloride) | 2 | 35 | 4 |
1 to 10 of 76Source ClinicalTrials.gov
See all 76 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Pazopanib Hydrochloride) | 19 | 35 |
| Total, other adverse events | Treatment (Pazopanib Hydrochloride) | 34 | 35 |
| Total, serious adverse events | Treatment (Pazopanib Hydrochloride) | 10 | 35 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | WILLMAN, CHERYL LYNN | MAYO CLINIC ROCHESTER | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01767636
GET https://conductscience.org/api/trials/v1/NCT01767636/events?page=2